To include your compound in the COVID-19 Resource Center, submit it here.

Arixtra fondaparinux: Phase III; marketed to prevent VE in patients undergoing hip refractory surgery, hip replacement surgery, or knee replacement surgery

In the international, double-blind, placebo-controlled Phase III ARTEMIS trial in 849 patients, the incidence of VE was 5.6%

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE